Navigation Links
Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
Date:11/10/2008

profit 35.7 23.3 20.4

Other income/(expense), net (2.9) (1.3) (3.5)

Income tax expense (1) 9.0 0.5 7.5

Income from continuing operations $23.8 $21.5 $9.4

Diluted earnings per share:

Earnings per share from continuing

operations $0.38 $0.34 $0.15

Average common shares outstanding -

diluted (thousands) 62,734 62,655 62,566

Dividends per common share $0.1025 $0.1025 $0.2850

Consolidated Cash Flows from

Operations (2)

Cash flow from operations $43.3 $23.0 $84.1

Less: capital expenditures (25.3) (20.6) (30.7)

Consolidated free cash flow $18.0 $2.4 $53.4

Cash and cash equivalents $221.7 $131.2 $145.9

Investment securities (3) $44.9 $46.2 $48.6

Hill-Rom Capital Expenditures $25.3 $20.6 $28.7

Hill-Rom Depreciation & Amortization $28.1 $25.5 $25.5

Hill-Rom Holdings, Inc.

Condensed Financial Information

Unaudited

(Dollars in millions except per share data)

Quarterly Periods

1Q08 4Q07

Condensed Statement of Earnings

Net revenues

Capital sales $229.5 $276.6

Rental revenues 111.9 95.4

Total revenues 341.4 372.0

Cost of revenues

Cost of go
'/>"/>

SOURCE Hill-Rom Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
3. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
4. BMP Sunstone Reports Third Quarter 2008 Financial Results
5. Endocare Reports Financial Results for Third Quarter 2008
6. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
7. Isis Reports Financial Results and Highlights for Third Quarter of 2008
8. OncoGenex Reports Third Quarter Financial Results
9. American Oriental Bioengineering Reports Third Quarter 2008 Financial Results
10. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
11. Dendreon Reports Third Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...Newswire/ -- TechConnect World, an event bringing ... product integration in cleantech, nanotech, biote...for technology abstracts and business presentation...in association with the Nano Science and Technolog...ustainable Industries Organization (CTSI), will br...
(Date:12/2/2009)...e/ -- S*BIO Pte Ltd today announced data presentat...The American Society of Hematology 51st Annual Mee...l be presented on the clinical results from the Ph...s safety, tolerability and pharmacokinetic/pharmac...om 100 to 600 mg. These doses were administered on...
(Date:12/2/2009)...ewswire-Asia/ -- Simcere Pharmaceutical Group,("Si... pharmaceutical company,specializing in the develo...eric and proprietary pharmaceuticals in China, tod...ded in China,s National Drug Reimbursement List,("...man Resources and Social,Security on November 30, ...
(Date:12/2/2009)...e-Asia/ -- The world is going through,extraordinar... part of many,businesses and industries. It turns ...mmune to the economic downturn, because illness do... of the difficult times this year, the pharmaceuti...mp;D center in Shanghai, the largest of,its kind i...
Breaking Biology Technology:Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
...ept. 5 /PRNewswire/ - GenoLogics, a leading develo...for life sciences research,announced today the Com...(TM) Applications Program, and its Geneus product ...he Affymetrix, Inc. (Nasdaq:,AFFX) GeneChip(R) mic...ated,its Geneus solution, built for multiple genom...
...ll review common U.S. laws on research and process...nce solutions, ST. LOUIS, Sept. 5 Sigma-Aldrich ...gazine, will present a Web,conference on laborator...1,p.m. EST. The online conference will review comm...d process laboratories and provide attendees,with ...
...., Sept. 5 A study in the August 2007,issue of Pe...,1,5-anhydroglucitol (1,5-AG) blood test to evalua...o target postprandial hyperglycemia (elevated,afte...cose levels is,important in achieving optimal glyc...ular complications, the leading cause of death in ...
Other Biology Technology:GenoLogics' Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform 2GenoLogics' Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform 3Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 2Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies 3Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes 2
(Date:12/1/2009)...s have two different feeding strategies. A large ...ng that they are generalist predators feeding on o... Some, however, are "herbivorous". This is not t...of their diets consist of plant-derived matter. Fo...y plants to attract ants, called extra-floral nect...
(Date:12/1/2009)...iNose is pleased to announce the publication of re...ng the efficacy and tolerability of its novel, int...ent of chronic rhinosinusitis with nasal polyps in...ional and European Rhinologic Societies. , Chro...disease that can significantly reduce a patient,s ...
(Date:12/1/2009)...imer,s disease, nerve cell degeneration plays a cr... may possibly be derived from steering the generat...e been published in the current issue of the renow...w years ago, neurogenesis the process of nerve ce... the adult brain. The textbooks asserted that dead...
Breaking Biology News(10 mins):Bacterial gut symbionts are tightly linked with the evolution of herbivory in ants 2New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2New source discovered for the generation of nerve cells in the brain 2Intensive Dialysis Doesnt Save Lives of the Sickest 59940 1Intensive Dialysis Doesnt Save Lives of the Sickest 59940 2Intensive Dialysis Doesnt Save Lives of the Sickest 59940 3Sex of Twins May Affect Outcomes 59938 1Sex of Twins May Affect Outcomes 59938 2Sex of Twins May Affect Outcomes 59938 3Pitt NIH team find way to protect healthy cells from radiation damage 59936 1Pitt NIH team find way to protect healthy cells from radiation damage 59936 2
...ve shown for the first time that carbon nanotubes ...ue. The new technique could change the way doctors...t a solution of nanotubes into a fracture to promo...sue of the American Chemical Society,s journal Che...ientific society. , The success of a bone graft d...
...it felt the last time you burned your finger on a ...ning pain in your hands or feet all the time and k... , David Fink, M.D.It,s called neuropathic pain, ...d medical conditions, especially diabetes. Drugs h...aused by damage to sensory neurons that transmit p...
... California, San Diego biochemists have developed ...ing mystery: how the same proteins can play differ...ncluding those leading to immune responses and can...re published in the September 16 issue of the jour... a computational approach could represent the intr...
Other Biology News:Nanotubes inspire new technique for healing broken bones 2Nanotubes inspire new technique for healing broken bones 3Scientists use gene transfer technology and common virus to block neuropathic pain in animals 2Scientists use gene transfer technology and common virus to block neuropathic pain in animals 3Scientists use gene transfer technology and common virus to block neuropathic pain in animals 4Scientists use gene transfer technology and common virus to block neuropathic pain in animals 5Computer modeling reveals hidden conversations within cells 2Computer modeling reveals hidden conversations within cells 3
Recorder REC-111 single-channel from GE Healthcare, formerly Amersham Biosciences
...or when you need to make your strain of cells comp...cy. Our services for preparing competent cells are...tions. MCLab's custom competent cell service offer...Fast turnaround Quality control performance test...
MEK1, total EIA Kit from Assay Designs/Stressgen Bioreagents
Argon Calibration Source from Ocean Optics
Biology Products: